scholarly journals Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　― 1-Year Follow-up Results of a Postmarketing Observational Study ―

2019 ◽  
Vol 84 (1) ◽  
pp. 101-108 ◽  
Author(s):  
Masato Nakamura ◽  
Takanari Kitazono ◽  
Ken Kozuma ◽  
Toru Sekine ◽  
Shinya Nakamura ◽  
...  
Keyword(s):  
Heart Disease ◽  
Clinical Practice ◽  
Observational Study ◽  
Ischemic Heart Disease ◽  
Japanese Patients ◽  
Ischemic Heart

scholarly journals Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　― Final 2-Year Follow-up Results of a Postmarketing Observational Study ―

2020 ◽  
Vol 84 (11) ◽  
pp. 1981-1989
Author(s):  
Masato Nakamura ◽  
Takanari Kitazono ◽  
Ken Kozuma ◽  
Toru Sekine ◽  
Shinya Nakamura ◽  
...  
Keyword(s):  
Heart Disease ◽  
Clinical Practice ◽  
Observational Study ◽  
Ischemic Heart Disease ◽  
Japanese Patients ◽  
Ischemic Heart

scholarly journals Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　― A 3-Month Interim Analysis of a Postmarketing Observational Study ―

2019 ◽  
Vol 83 (3) ◽  
pp. 637-646 ◽  
Author(s):  
Masato Nakamura ◽  
Ken Kozuma ◽  
Takanari Kitazono ◽  
Tomoko Iizuka ◽  
Toru Sekine ◽  
...  
Keyword(s):  
Heart Disease ◽  
Clinical Practice ◽  
Observational Study ◽  
Ischemic Heart Disease ◽  
Interim Analysis ◽  
Japanese Patients ◽  
Ischemic Heart

scholarly journals Changes in Aerobic Capacity and Coronary Risk Factors during Long-term Exercise Training in Women with Ischemic Heart Disease: A 36-month Follow-up.

1996 ◽  
Vol 15 (3) ◽  
pp. 115-121 ◽  
Author(s):  
Masaki Takeda ◽  
Kiyoji Tanaka ◽  
Hideya Unno ◽  
Teruo Hiyama ◽  
Katsumi Asano
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Exercise Training ◽  
Ischemic Heart Disease ◽  
Aerobic Capacity ◽  
Ischemic Heart ◽  
Coronary Risk Factors ◽  
Coronary Risk

Long-term follow-up of the Ischemic Heart Disease Life Stress Monitoring Program.

1989 ◽  
Vol 51 (5) ◽  
pp. 485-513 ◽  
Author(s):  
N Frasure-Smith ◽  
R Prince
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Life Stress ◽  
Monitoring Program ◽  
Ischemic Heart ◽  
Stress Monitoring ◽  
Long Term Follow Up

scholarly journals Efficacy, Safety and Long-term Outcomes of Nicorandil Use in Patients with Stable Ischemic Heart Disease According to the Results of Randomized and Observational Studies

2019 ◽  
Vol 15 (5) ◽  
pp. 641-648
Author(s):  
Yu. V. Lukina ◽  
N. P. Kutishenko ◽  
S. Yu. Martsevich
Keyword(s):  
Heart Disease ◽  
Clinical Practice ◽  
Comparative Analysis ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Long Term Outcomes ◽  
Stable Ischemic Heart Disease ◽  
The Impact ◽  
Real Clinical Practice

Working Group of the NIKEA Study. Yekaterinburg: Akulina E.N., Reznik I.I.; Izhevsk: Grebnev S.A., Yezhov A., Shinkareva S.E.; Krasnodar: Kudryashov E.A., Skibitsky A.V., Skibitsky V.V., Fendrikova A.V.; Krasnoyarsk: Altayev V.D., Matyushin G.V., Nemik D.B., Pitaev R.R., Samokhvalov E.V., Stolbikov Yu.Yu.; Moscow: Balashov I.S., Voronina V.P., Gaisenok O.V., Dmitrieva N.A., Zagrebelny A.V., Zakharova A.V., Zelenova T.I., Kolganova E.V., Leonov A.S., Lerman O.V., Maximova M.A., Sladkova T.A., Shestakova G.N.; Novosibirsk: Kuimov A.D., Shurkevich A.A.; Omsk: Goodilin V.A., Loginova E.N., Nechaeva G.I.; Orel: Zhuravleva L.L., Lobanova G.N., Luneva M.M., Mitroshina T.N.; Orenburg: Kondratenko V.Yu., Libis R.A.; Rostov-on-Don: Dubishcheva N.F., Kalacheva N.M., Kolomatskaya O.E., Romadina G., Skarzhinskaya N.S., Chesnikova A.I., Chugunova I.B.; Ryazan: Dobrynina N.V., Nikolaev A.S., Trofimova Ya.M., Yakushin S.S.; Tula: Berberfish L.D., Gomova T.A., Gorina G.I., Dabizha V.G., Zubareva L.A., Nadezhkina K.N., Nikitina V.F., Renko I.E., Soin I.A., Yunusova K.N.Background. Nicorandil is an antianginal drug for which, the ability to positively influence the prognosis of patients (pts) with stable ischemic heart disease (IHD) was confirmed in a randomized controlled trial (RCT) of IONA (the Impact Of Nicorandil in Angina). To study whether the results of RCTs are reproduced in real clinical practice seems to be an actual scientific and practical task.Aim. To compare the data on the effectiveness and safety of nicorandil in pts with stable IHD obtained in the NIKEA observational study (OS) and in the IONA randomized study.Material and methods. 590 pts with IHD and stable angina pectoris were included in the OS NIKEA. All pts were recommended to take nicorandil in addition to the standard antiischemic therapy. 21 months after being included in the study, 524 pts received a phone call. During the telephone contact with pts or their relatives, the life status of pts was determined. According to these results of the survey data were obtained, that 15 people died and 509 pts were alive. The events included in the primary combined endpoint (PCEP) were also determined: death from all causes, new cases of acute myocardial infarction and acute cerebrovascular accident, unscheduled operations of myocardial revascularization, hospitalization for decompensation of chronic heart failure, atrial fibrillation, unstable angina, information on taking nicorandil and other drug therapy, adverse events of drug treatment have been reported. A comparative analysis of the results of the OS NIKEA and RCT IONA was carried out. The results of the IONA study were taken according to the publication in the Lancet 2002. A comparative analysis of the results of the effectiveness of nicorandil in real practice (according to the OS results) was performed with the data obtained in the RCT: the nicorandil/placebo groups in the RCT were compared with the adherent/non-adherent nicorandil groups in the OS.Results. The follow-up duration in both studies was similar and averaged 1.6±0.5 years at RCT IONA and 1.8±0.4 years at NIKEA study. The average age of pts was 67,0±8,0 years in RCT and 65.1±9.6 years in OS. In pts of OS more pronounced comorbidity was noted (cardiovascular diseases, diabetes mellitus). Drugs that favorably affect the prognosis in pts with IHD were more often prescribed to NIKEA study pts (p<0.05). In both RCTs and OS, the antianginal effectiveness of nicorandil was confirmed. According to the OS results, a reduction in the number of angina attacks and a decrease in the need for short-acting nitrates were demonstrated. The frequency of PCEP components was higher in RCT.Conclusion. Long-term outcomes according to the NIKEA observational program for various components of the PCEP turned out to be similar to the results of RCT IONA. It is demonstrated the efficacy of nicorandil in real clinical practice. 

Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up

1999 ◽  
Vol 51 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Janny G. Reinders ◽  
Ben J.M. Heijmen ◽  
Manouk J.J. Olofsen-van Acht ◽  
Wim L.J. van Putten ◽  
Peter C. Levendag
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Ischemic Heart ◽  
Long Term Follow Up

scholarly journals SO028LONG-TERM OUTCOMES IN LIVE KIDNEY DONORS: PREVALENCE OF ISCHEMIC HEART DISEASE, DIABETES, CANCER AND CEREBROVASCULAR DISEASE AFTER DONATION COMPARED TO HEALTHY CONTROLS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Anders Haugen ◽  
Dag Olav Dahle ◽  
Stein I Hallan ◽  
Karsten Midtvedt ◽  
Anna Varberg Reisater ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Cerebrovascular Disease ◽  
Ischemic Heart ◽  
Healthy Controls ◽  
Kidney Donors ◽  
Increased Risk ◽  
Long Term Follow Up

Abstract Background and Aims During long-term follow-up kidney donors are at increased risk of hypertension and end-stage renal disease after donation. Hypertension is a known risk factor for development of cardiovascular disease, but it is unknown whether kidney donors are at increased risk of cardiovascular disease. We evaluated a large Norwegian kidney donor cohort and assessed prevalence of ischemic heart disease after donation compared to healthy controls. Prevalence of cancer, diabetes and cerebrovascular disease was also calculated. Method Follow-up data were retrospectively retrieved from past kidney donors. Healthy non-donor controls from a general population screening study were selected. Controls were selected according to standard donation criteria, assessed in similar time periods as the living donors. Stratified logistic regression was used to estimate associations with various disease outcomes. The diagnoses at follow-up were self-reported for the controls and registered by a physician for the donors. A total of 1029 donors and 16084 controls were included. Results Mean observation time was eleven years after donation. Forty-four per cent of donors were male and mean age at follow-up was 56 years. Among the controls, 39 % were male and mean age at follow-up was 53 years. At the time of follow up, 3.5 % of donors vs 1.7 % of controls had been diagnosed with ischemic heart disease, 3.7 % vs 4.4 % cancer, 1.8 % vs 1.4 % cerebrovascular disease and 4.1 % vs 1.9 % diabetes. After adjusting for gender, age at follow up, smoking at baseline, BMI at baseline, systolic blood pressure at baseline and time since donation (time since participation in general population survey for controls), odds ratio for ischemic heart disease was 1.64 (CI 1.10-2.43; P=0.01) in previous kidney donors compared with healthy controls. Other outcomes did not differ significantly between donors and controls. Conclusion During long-term follow-up of kidney donors we find an increased risk of ischemic heart disease compared to healthy controls. This information may be important in the follow-up and selection process of living kidney donors.

Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: Long-term follow-up of the HUNT 1 study

2010 ◽  
Vol 212 (2) ◽  
pp. 614-620 ◽  
Author(s):  
Inga Thorsen Vengen ◽  
Ane Cecilie Dale ◽  
Rune Wiseth ◽  
Kristian Midthjell ◽  
Vibeke Videm
Keyword(s):  
Diabetes Mellitus ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
Ischemic Heart ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document